GMAB
HEALTHCAREGenmab
$27.89+0.37 (+1.34%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GMAB Today?
No stock-specific AI insight has been generated for GMAB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$18.89$35.43
$27.89
Fundamentals
Market Cap$17.1B
P/E Ratio18.1
EPS$1.54
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.3%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding613.9M
GMAB News
22 articles- Genmab A/S Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion pushYahoo Finance·May 7, 2026
- Genmab Announces Financial Results for the First Quarter of 2026Yahoo Finance·May 7, 2026
- Genmab (GMAB) Rated Outperform on Oncology PipelineYahoo Finance·May 2, 2026
- Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst OutlookYahoo Finance·Apr 24, 2026
- BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?Yahoo Finance·Apr 22, 2026
- Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidenceYahoo Finance·Apr 22, 2026
- Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development PlatformsGlobeNewswire Inc.·Apr 21, 2026
- Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & OutlookGlobeNewswire Inc.·Apr 21, 2026
- Genmab (CPSE:GMAB) Valuation Check After Mixed Recent Share PerformanceYahoo Finance·Apr 20, 2026
- Genmab A/S Share Capital ReductionGlobeNewswire Inc.·Apr 17, 2026
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026Yahoo Finance·Apr 14, 2026
- Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian CancerYahoo Finance·Apr 13, 2026
- Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsYahoo Finance·Apr 1, 2026
- A Look At Genmab’s (CPSE:GMAB) Valuation After Recent Share Price VolatilityYahoo Finance·Apr 1, 2026
- Major Shareholder AnnouncementGlobeNewswire Inc.·Mar 30, 2026
- Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst callsYahoo Finance·Mar 27, 2026
- Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More247 Wall St·Mar 27, 2026
- Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab ReadoutsYahoo Finance·Mar 26, 2026
- Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation DebateYahoo Finance·Mar 20, 2026
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in GenmabYahoo Finance·Mar 19, 2026
- Passing of Genmab A/S’ Annual General MeetingYahoo Finance·Mar 19, 2026
All 22 articles loaded
Price Data
Open$27.58
Previous Close$27.52
Day High$28.00
Day Low$27.50
52 Week High$35.43
52 Week Low$18.89
52-Week Range
$18.89$35.43
$27.89
Fundamentals
Market Cap$17.1B
P/E Ratio18.1
EPS$1.54
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.3%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding613.9M
About Genmab
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—